GTTX — GeneTether Therapeutics Balance Sheet
0.000.00%
- CA$1.94m
- CA$0.22m
- 50
- 38
- 73
- 53
Annual balance sheet for GeneTether Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 0.013 | 0.045 | 0.18 | 1.8 | 1.36 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 0.013 | 0.045 | 0.37 | 1.94 | 1.41 |
Total Assets | 0.013 | 0.045 | 0.37 | 1.94 | 1.41 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 0.021 | 0.123 | 0.213 | 0.087 | 0.039 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 0.021 | 0.123 | 0.213 | 0.087 | 0.039 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -0.008 | -0.078 | 0.157 | 1.86 | 1.37 |
Total Liabilities & Shareholders' Equity | 0.013 | 0.045 | 0.37 | 1.94 | 1.41 |
Total Common Shares Outstanding |